Journals / Acta Medica Nicomedia / 2026 / Cilt: 9

IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY

İMMÜNOTERAPİ ALAN 75 YAŞ VE ÜZERİ KANSER HASTALARINDA İMMÜN İLİŞKİLİ YAN ETKİLER VE YÖNETİMİ

Buket Şahin Çelik(Bursa Ali Osman Sönmez Oncology Hospital)0009-0006-0816-5397
Hülya Ertaş(Bursa Ali Osman Sönmez Oncology Hospital)0000-0002-5872-8825
Gözde Ağdaş(Van Training and Research Hospital)0000-0001-9771-6483
Pages
1–8
Publication Date
2026-10-30
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

These findings contribute to characterizing irAEs in elderly patients; however, larger prospective studies are needed to clarify immunotherapy safety in this population.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs).
📊
Key Findings & Data:This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients aged ≥75 years.
💡
Conclusion & Impact:These findings contribute to characterizing irAEs in elderly patients; however, larger prospective studies are needed to clarify immunotherapy safety in this population.
🔬Design:Araştırma Makalesi
📍Scope:Comprehensive Sample
⚙️Variables:İmmünoterapi · İmmün İlişkili Yan Etkiler · Toksisite Yönetimi

Abstract

Objective: Immune checkpoint inhibitors (ICIs) have improved cancer treatment outcomes but may cause immune-related adverse events (irAEs). Data regarding immunotherapy safety in elderly patients remain limited. This study aimed to evaluate irAE distribution, severity, and associated clinical factors in cancer patients aged ≥75 years. Methods: This retrospective observational study included all consecutive cancer patients aged ≥75 years who received ICIs at our institution during the study period. All 60 eligible patients experienced at least one irAE. Demographic and clinical characteristics, treatment details, steroid requirement, and treatment continuation status were recorded. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Descriptive statistics, Pearson's chi-square tests, and Classification and Regression Tree (CRT) analysis were performed. Results: Endocrine toxicities were most frequent (18.3%), followed by renal toxicities (15.0%). Cutaneous, neurological, and pulmonary toxicities each occurred in 10.0% of patients. No significant associations were observed between irAE grade and age, sex, treatment line, ICI type, or treatment cycle at onset (p > 0.05). Steroid requirement was significantly associated with irAE grade (χ² = 24.061, p < 0.001), whereas treatment continuation status was not (χ² = 7.657, p = 0.105). Conclusion: ICIs demonstrated a spectrum of irAEs requiring clinical management in elderly patients. Demographic factors were not significantly associated with toxicity severity, whereas steroid requirement was associated with higher toxicity grades. These findings contribute to characterizing irAEs in elderly patients; however, larger prospective studies are needed to clarify immunotherapy safety in this population.

Özet

Amaç: İmmün kontrol noktası inhibitörleri (ICI), kanser tedavisinde klinik sonuçları iyileştirmiş olmakla birlikte, immün ilişkili advers olaylara (irAE) neden olabilmektedir. İleri yaş hastalarda immünoterapinin güvenliliğine ilişkin veriler halen sınırlıdır. Bu çalışmada, 75 yaş ve üzerindeki kanser hastalarında immün ilişkili advers olayların dağılımının, şiddetinin ve bunlarla ilişkili klinik faktörlerin değerlendirilmesi amaçlandı. Yöntem: This retrospective observational study included all consecutive cancer patients aged ≥75 years who received ICIs at our institution during the study period. All 60 eligible patients experienced at least one irAE. Demographic and clinical characteristics, treatment details, steroid requirement, and treatment continuation status were recorded. Adverse events were graded according to the Common Terminology Criteria for Adverse Events (CTCAE). Descriptive statistics, Pearson's chi-square tests, and Classification and Regression Tree (CRT) analysis were performed. Bulgular: Endocrine toxicities were most frequent (18.3%), followed by renal toxicities (15.0%). Cutaneous, neurological, and pulmonary toxicities each occurred in 10.0% of patients. No significant associations were observed between irAE grade and age, sex, treatment line, ICI type, or treatment cycle at onset (p > 0.05). Steroid requirement was significantly associated with irAE grade (χ² = 24.061, p < 0.001), whereas treatment continuation status was not (χ² = 7.657, p = 0.105). Sonuç: ICIs demonstrated a spectrum of irAEs requiring clinical management in elderly patients. Demographic factors were not significantly associated with toxicity severity, whereas steroid requirement was associated with higher toxicity grades. These findings contribute to characterizing irAEs in elderly patients; however, larger prospective studies are needed to clarify immunotherapy safety in this population.

🔖

Cite This Article

Çelik, B. Ş., Ertaş, H., Ağdaş, G. (2026). IMMUNE-RELATED ADVERSE EVENTS AND THEIR MANAGEMENT IN CANCER PATIENTS AGED 75 YEARS AND OLDER RECEIVING IMMUNOTHERAPY. Acta Medica Nicomedia, Cilt: 9, 1–8. https://doi.org/10.53446/actamednicomedia.1906747

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249. doi:10.3322/caac.21660
  2. White MC, Holman DM, Boehm JE, et al. Age and cancer risk: a potentially modifiable relationship. Am J Prev Med. 2014;46(3 Suppl 1):S7-S15. doi:10.1016/j.amepre.2013.10.029
  3. Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12(4):252-264. doi:10.1038/nrc3239
  4. Topalian SL, Drake CG, Pardoll DM. Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015;27(4):450-461. doi:10.1016/j.ccell.2015.03.001
  5. Postow MA, Sidlow R, Hellmann MD. Immune-related adverse events associated with immune checkpoint blockade. N Engl J Med. 2018;378(2):158-168. doi:10.1056/NEJMra1703481
  6. Wang DY, Salem JE, Cohen JV, et al. Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis. JAMA Oncol. 2018;4(12):1721-1728. doi:10.1001/jamaoncol.2018.3923
  7. Brahmer JR, Lacchetti C, Schneider BJ, et al. Management of immune-related adverse events in patients treated with immune checkpoint inhibitor therapy. J Clin Oncol. 2018;36(17):1714-1768. doi:10.1200/JCO.2017.77.6385 Haanen JBAG, Carbonnel F, Robert C, et al. Management of toxicities from immunotherapy: ESMO clinical practice guidelines. Ann Oncol. 2017;28(Suppl 4):iv119-iv142. doi:10.1093/annonc/mdx225
  8. Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51-60. doi:10.1016/j.ctrv.2016.02.001
  9. Nikolich-Žugich J. The twilight of immunity: emerging concepts in aging of the immune system. Nat Immunol. 2018;19(1):10-19. doi:10.1038/s41590-017-0006-x
  10. Elias R, Morales J, Rehman Y, et al. Immune checkpoint inhibitors in older adults with cancer. J Geriatr Oncol. 2016;7(6):470-475. doi:10.1016/j.jgo.2016.07.006
  11. Extermann M, Aapro M. Assessment of the older cancer patient. Hematol Oncol Clin North Am. 2000;14(1):63-77. doi:10.1016/S0889-8588(05)70280-9
  12. Nishijima TF, Muss HB, Shachar SS, et al. Comparison of efficacy of immune checkpoint inhibitors between younger and older patients: a systematic review and meta-analysis. Cancer Treat Rev. 2016;45:30-37. doi:10.1016/j.ctrv.2016.02.006
  13. Ferrara R, Mezquita L, Auclin E, et al. Immunosenescence and immune checkpoint inhibitors in non-small cell lung cancer patients: does age really matter? Lung Cancer. 2017;108:71-79. doi:10.1016/j.lungcan.2017.03.011
  14. Balducci L, Extermann M. Management of cancer in the older person: a practical approach. Oncologist. 2000;5(3):224-237. doi:10.1634/theoncologist.5-3-224
  15. Sharma P, Hu-Lieskovan S, Wargo JA, et al. Primary, adaptive, and acquired resistance to cancer immunotherapy. Cell. 2017;168(4):707-723. doi:10.1016/j.cell.2017.01.017
  16. Michot JM, Bigenwald C, Champiat S, et al. Immune-related adverse events with immune checkpoint blockade: a comprehensive review. Eur J Cancer. 2016;54:139-148. doi:10.1016/j.ejca.2015.11.016
  17. Friedman CF, Proverbs-Singh TA, Postow MA. Treatment of immune-related adverse effects of immune checkpoint inhibitors. JAMA Oncol. 2016;2(10):1346-1353. doi:10.1001/jamaoncol.2016.1051